PMR 116
Alternative Names: PMR-116Latest Information Update: 24 Jun 2024
At a glance
- Originator Pimera
- Class Antineoplastics; Small molecules
- Mechanism of Action RNA polymerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia; B-cell lymphoma; Liver cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma
Most Recent Events
- 24 Jun 2024 PMR 116 is still in phase-I trial in Solid-tumours(Late-stage disease) in Australia (PO, Liquid) (ACTRN12620001146987)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research(AACR-2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (PO, Liquid)